Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning for Stem Cell Transplantation.

被引：0
|
作者：
Bremer, S. [1 ]
Floeisand, Y. [2 ]
Bergan, S. [3 ,4 ]
机构：
[1] Oslo Univ Hosp, Dept Med Biochem, Oslo, Norway
[2] Oslo Univ Hosp, Dept Hematol, Oslo, Norway
[3] Oslo Univ Hosp, Dept Pharmacol, Oslo, Norway
[4] Univ Oslo, Sch Pharm, Oslo, Norway
来源：
TRANSPLANTATION | 2014年 / 98卷
关键词：
D O I：
10.1097/00007890-201407151-03003
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
A30
引用
收藏
页码：880 / 880
页数：1
相关论文
共 50 条
  • [21] Comparison Between Busulfan with Cyclophosphamide and Busulfan with Fludarabine As Myeloablative Conditioning of Allogeneic Hematopoietic Stem Cell Transplantation for Myeloid Malignancies
    Mori, Takehiko
    Ohashi, Kazuteru
    Kanamori, Heiwa
    Sakura, Toru
    Yano, Shingo
    Kanda, Yoshinobu
    Kako, Shinichi
    Tachibana, Takayoshi
    Yokota, Akira
    Onizuka, Makoto
    Nakaseko, Chiaki
    Okamoto, Shinichiro
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S204 - S204
  • [22] Incidence and outcome of thrombotic microangiopathy after allogeneic peripheral blood stem cell transplantation with non-myeloablative conditioning compared with myeloablative conditioning
    Willems, E
    Baron, F
    Fillet, G
    Beguin, Y
    BONE MARROW TRANSPLANTATION, 2006, 37 : S46 - S46
  • [23] Influence of human platelet antigen match on the success of stem cell transplantation after myeloablative conditioning
    Leitner, GC
    Tanzmann, A
    Stiegler, G
    Kalhs, P
    Greinix, HT
    Hoecker, P
    Panzer, S
    BONE MARROW TRANSPLANTATION, 2003, 32 (08) : 821 - 824
  • [24] Influence of human platelet antigen match on the success of stem cell transplantation after myeloablative conditioning
    G C Leitner
    A Tanzmann
    G Stiegler
    P Kalhs
    H T Greinix
    P Hoecker
    S Panzer
    Bone Marrow Transplantation, 2003, 32 : 821 - 824
  • [25] Preliminary results of an non-myeloablative conditioning regimen for allogeneic stem cell transplantation.
    Mackinnon, S
    Kottaridis, P
    Perry, A
    Chakrabarti, S
    Milligan, DW
    Pettengell, R
    Chopra, R
    Morgan, G
    Hale, G
    Waldmann, H
    Linch, DC
    Devereux, S
    Goldstone, AH
    BRITISH JOURNAL OF HAEMATOLOGY, 1999, 105 : 31 - 31
  • [26] Posttransplant lymphoproliferative disorder after non myeloablative stem cell transplantation.
    Arat, H
    Gürman, G
    Çelebi, H
    Soydan, E
    Kuzu, I
    Koç, H
    BLOOD, 2000, 96 (11) : 345B - 345B
  • [27] POPULATION PHARMACOKINETICS OF BUSULFAN IN SAUDI PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION.
    Albassam, A.
    Alsultan, A.
    Alturki, A.
    Alfadhel, S.
    AlMuzaini, B.
    Essa, M.
    AlSultan, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S96 - S97
  • [28] Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics
    ten Brink, M. H.
    Zwaveling, J.
    Swen, J. J.
    Bredius, R. G. M.
    Lankester, A. C.
    Guchelaar, H. J.
    DRUG DISCOVERY TODAY, 2014, 19 (10) : 1572 - 1586
  • [29] Impact of obesity on outcome after stem cell transplantation.
    Fleming, DR
    Rayens, MK
    Garrison, J
    BLOOD, 1996, 88 (10) : 3744 - 3744
  • [30] Progressive disease after non-myeloablative allogeneic stem cell transplantation.
    Bolwell, BJ
    Pohlman, B
    Sobecks, R
    Andresen, S
    Theil, KS
    Brown, S
    Bernhard, L
    Curtis, J
    Koennecke, J
    Kosar, J
    Ostendorf, H
    Sands, K
    Serafin, M
    Kalaycio, M
    BLOOD, 2002, 100 (11) : 634A - 634A
12345